Truist raised the firm’s price target on Aramark (ARMK) to $50 from $46 and keeps a Buy rating on the shares. The company’s organic growth paced ahead of the firm’s expectations and Aramark cited another large contract win with RWJ Barnabas Health due to begin ramping in June 2026, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARMK: